{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:32:07Z","timestamp":1780374727891,"version":"3.54.1"},"reference-count":68,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2016,4,6]],"date-time":"2016-04-06T00:00:00Z","timestamp":1459900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background.<\/jats:title>\n                  <jats:p>Everolimus, an oral mTOR (mammalian target of rapamycin) inhibitor, is currently approved for the treatment of progressive pancreatic neuroendocrine tumors (NETs). Although promising, only scattered data, often from nondedicated studies, are available for extrapancreatic NETs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and Methods.<\/jats:title>\n                  <jats:p>A systematic review of the published data was performed concerning the use of everolimus in extrapancreatic NET, with the aim of summarizing the current knowledge on its efficacy and tolerability. Moreover, the usefulness of everolimus was evaluated according to the different sites of the primary.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>The present study included 22 different publications, including 874 patients and 456 extrapancreatic NETs treated with everolimus. Nine different primary sites of extrapancreatic NETs were found. The median progression-free survival ranged from 12.0 to 29.9 months. The median time to progression was not reached in a phase II prospective study, and the interval to progression ranged from 12 to 36 months in 5 clinical cases. Objective responses were observed in 7 prospective studies, 2 retrospective studies, and 2 case reports. Stabilization of the disease was obtained in a high rate of patients, ranging from 67.4% to 100%. The toxicity of everolimus in extrapancreatic NETs is consistent with the known safety profile of the drug. Most adverse events were either grade 1 or 2 and easy manageable with a dose reduction or temporary interruption and only rarely requiring discontinuation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion.<\/jats:title>\n                  <jats:p>Treatment with everolimus in patients with extrapancreatic NETs appears to be a promising strategy that is safe and well tolerated. The use of this emerging opportunity needs to be validated with clinical trials specifically designed on this topic.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2015-0420","type":"journal-article","created":{"date-parts":[[2016,4,7]],"date-time":"2016-04-07T05:24:12Z","timestamp":1460006652000},"page":"875-886","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature"],"prefix":"10.1093","volume":"21","author":[{"given":"Antongiulio","family":"Faggiano","sequence":"first","affiliation":[{"name":"Thyroid and Parathyroid Surgery Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori \u201cFondazione G. Pascale\u201d \u2013 IRCCS, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasqualino","family":"Malandrino","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Garibaldi Nesima Medical Center, Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Modica","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Agrimi","sequence":"additional","affiliation":[{"name":"District Hospital, Azienda Sanitaria Locale, Brindisi, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Aversano","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Azienda Sanitaria Locale Napoli 3, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Bassi","sequence":"additional","affiliation":[{"name":"Unit of Internal Medicine, San Giovanni Bosco Hospital, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto A.","family":"Giordano","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Azienda Sanitaria Provinciale di Calabria, Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Guarnotta","sequence":"additional","affiliation":[{"name":"Biomedical Department of Internal and Specialist Medicine, Section of Endocrinology, University of Palermo, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco A.","family":"Logoluso","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Azienda Ospedaliero-Universitaria Consorziale Policlinico, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Messina","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Nicastro","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliero-Universitaria \u201cOspedali Riuniti,\u201d Foggia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Nuzzo","sequence":"additional","affiliation":[{"name":"Unit of Internal Medicine, San Gennaro Hospital, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Sciaraffia","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, SS Annunziata Hospital, Taranto, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Colao","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,4,6]]},"reference":[{"key":"2021122309580268300_B1","doi-asserted-by":"crossref","first-page":"R153","DOI":"10.1530\/ERC-13-0125","article-title":"Incidence of gastroenteropancreatic neuroendocrine tumours: A systematic review of the literature","volume":"21","author":"Fraenkel","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"2021122309580268300_B2","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122309580268300_B3","first-page":"817","article-title":"Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: The NET management study","volume":"35","author":"Faggiano","year":"2012","journal-title":"J Endocrinol Invest"},{"key":"2021122309580268300_B4","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122309580268300_B5","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/1097-0142(19930701)72:1<244::AID-CNCR2820720143>3.0.CO;2-Q","article-title":"Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors","volume":"72","author":"Saltz","year":"1993","journal-title":"Cancer"},{"key":"2021122309580268300_B6","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc1362","article-title":"The TOR pathway: A target for cancer therapy","volume":"4","author":"Bjornsti","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"2021122309580268300_B7","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrd2062","article-title":"Current development of mTOR inhibitors as anticancer agents","volume":"5","author":"Faivre","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"2021122309580268300_B8","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1200\/JCO.2008.20.0766","article-title":"Targeting the mTOR signaling network for cancer therapy","volume":"27","author":"Meric-Bernstam","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122309580268300_B9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1593\/tlo.09277","article-title":"Biomarker development for the clinical activity of the mTOR inhibitor everolimus (rad001): Processes, limitations, and further proposals","volume":"3","author":"O\u2019Reilly","year":"2010","journal-title":"Transl Oncol"},{"key":"2021122309580268300_B10","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s12020-014-0380-1","article-title":"PI3K\/Akt\/mTOR signaling in medullary thyroid cancer: A promising molecular target for cancer therapy","volume":"48","author":"Manfredi","year":"2015","journal-title":"Endocrine"},{"key":"2021122309580268300_B11","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1101\/gad.1212704","article-title":"Upstream and downstream of mTOR","volume":"18","author":"Hay","year":"2004","journal-title":"Genes Dev"},{"key":"2021122309580268300_B12","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","article-title":"TOR signaling in growth and metabolism","volume":"124","author":"Wullschleger","year":"2006","journal-title":"Cell"},{"key":"2021122309580268300_B13","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1200\/JCO.2009.24.2669","article-title":"Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: A phase II trial","volume":"28","author":"Yao","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122309580268300_B14","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1200\/JCO.2008.16.7858","article-title":"Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: Results of a phase II study","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122309580268300_B15","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1002\/cncr.28726","article-title":"Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: An ITMO group study","volume":"120","author":"Bajetta","year":"2014","journal-title":"Cancer"},{"key":"2021122309580268300_B16","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1634\/theoncologist.2012-0263","article-title":"Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: A subgroup analysis of the phase III RADIANT-2 study","volume":"18","author":"Castellano","year":"2013","journal-title":"The Oncologist"},{"key":"2021122309580268300_B17","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1378\/chest.12-1108","article-title":"Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: Analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study","volume":"143","author":"Fazio","year":"2013","journal-title":"Chest"},{"key":"2021122309580268300_B18","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): A randomised, placebo-controlled, phase 3 study","volume":"378","author":"Pavel","year":"2011","journal-title":"Lancet"},{"key":"2021122309580268300_B19","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1634\/theoncologist.2014-0037","article-title":"Real-world study of everolimus in advanced progressive neuroendocrine tumors","volume":"19","author":"Panzuto","year":"2014","journal-title":"The Oncologist"},{"key":"2021122309580268300_B20","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): A randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"key":"2021122309580268300_B21","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00280-013-2118-9","article-title":"Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors","volume":"71","author":"Chan","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122309580268300_B22","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1530\/ERC-11-0382","article-title":"Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors","volume":"19","author":"Chan","year":"2012","journal-title":"Endocr Relat Cancer"},{"key":"2021122309580268300_B23","doi-asserted-by":"crossref","first-page":"6162","DOI":"10.1002\/cncr.27675","article-title":"Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas\/paragangliomas","volume":"118","author":"Oh","year":"2012","journal-title":"Cancer"},{"key":"2021122309580268300_B24","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1093\/annonc\/mdt379","article-title":"A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes","volume":"24","author":"Lim","year":"2013","journal-title":"Ann Oncol"},{"key":"2021122309580268300_B25","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.2967\/jnumed.113.129056","article-title":"Everolimus reduces 89zr-bevacizumab tumor uptake in patients with neuroendocrine tumors","volume":"55","author":"Van Asselt","year":"2014","journal-title":"J Nucl Med"},{"key":"2021122309580268300_B26","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1530\/ERC-13-0254","article-title":"Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate","volume":"20","author":"Kamp","year":"2013","journal-title":"Endocr Relat Cancer"},{"key":"2021122309580268300_B27","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1159\/000354637","article-title":"Antitumor effect of everolimus in a patient with type 3 gastric neuroendocrine tumor","volume":"36","author":"Bariani","year":"2013","journal-title":"Onkologie"},{"key":"2021122309580268300_B28","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000350745","article-title":"Long-term management of a patient with well-differentiated pulmonary neuroendocrine carcinoma: A case report","volume":"6","author":"Beck","year":"2013","journal-title":"Case Rep Oncol"},{"key":"2021122309580268300_B29","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/annonc\/mdq670","article-title":"Control of carcinoid syndrome with everolimus","volume":"22","author":"Capdevila","year":"2011","journal-title":"Ann Oncol"},{"key":"2021122309580268300_B30","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1365-2265.2011.04296.x","article-title":"Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma","volume":"77","author":"Druce","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2021122309580268300_B31","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1111\/j.1582-4934.2011.01438.x","article-title":"Everolimus is an active agent in medullary thyroid cancer: A clinical and in vitro study","volume":"16","author":"Faggiano","year":"2012","journal-title":"J Cell Mol Med"},{"key":"2021122309580268300_B32","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.spinee.2014.09.027","article-title":"Neuroendocrine tumor arising from tailgut cyst with spinal cord tethering: Case report and literature review","volume":"15","author":"Mitsuyama","year":"2015","journal-title":"Spine J"},{"key":"2021122309580268300_B33","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1097\/IOP.0000000000000061","article-title":"Primary renal carcinoid metastatic to the orbit","volume":"31","author":"Parikh","year":"2015","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"2021122309580268300_B34","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3727\/096504011X13123323849799","article-title":"Compassionate use of everolimus in a patient with a neuroendocrine tumor: A case report and discussion of the literature","volume":"19","author":"Pusceddu","year":"2011","journal-title":"Oncol Res"},{"key":"2021122309580268300_B35","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/2047-783X-18-22","article-title":"Severe everolimus-induced steatohepatis: A case report","volume":"18","author":"Schieren","year":"2013","journal-title":"Eur J Med Res"},{"key":"2021122309580268300_B36","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1186\/1756-0500-6-471","article-title":"Severe hypersensitivity pneumonitis associated with everolimus therapy for neuroendocrine tumour: A case report","volume":"6","author":"Sibertin-Blanc","year":"2013","journal-title":"BMC Res Notes"},{"key":"2021122309580268300_B37","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.5858\/2009-0583-RAR.1","article-title":"Neuroendocrine tumors of the lung: An update","volume":"134","author":"Rekhtman","year":"2010","journal-title":"Arch Pathol Lab Med"},{"key":"2021122309580268300_B38","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/00000478-199106000-00003","article-title":"Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma: An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases","volume":"15","author":"Travis","year":"1991","journal-title":"Am J Surg Pathol"},{"key":"2021122309580268300_B39","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/MPA.0b013e3181ec1380","article-title":"NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: Well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus)","volume":"39","author":"Phan","year":"2010","journal-title":"Pancreas"},{"key":"2021122309580268300_B40","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1677\/ERC-10-0157","article-title":"Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung","volume":"17","author":"Righi","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"2021122309580268300_B41","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1677\/ERC-10-0097","article-title":"Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids","volume":"17","author":"Zatelli","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"2021122309580268300_B42","doi-asserted-by":"crossref","first-page":"R163","DOI":"10.1530\/ERC-12-0024","article-title":"Neuroendocrine tumor disease: An evolving landscape","volume":"19","author":"Frilling","year":"2012","journal-title":"Endocr Relat Cancer"},{"key":"2021122309580268300_B43","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.suc.2009.06.008","article-title":"Carcinoid tumors","volume":"89","author":"Pasieka","year":"2009","journal-title":"Surg Clin North Am"},{"key":"2021122309580268300_B44","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1196\/annals.1294.002","article-title":"The gastroenteropancreatic neuroendocrine cell system and its tumors: The WHO classification","volume":"1014","author":"Kl\u00f6ppel","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"2021122309580268300_B45","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ejso.2007.07.202","article-title":"Carcinoid syndrome","volume":"34","author":"Bendelow","year":"2008","journal-title":"Eur J Surg Oncol"},{"issue":"suppl 4","key":"2021122309580268300_B46","first-page":"iv1","article-title":"Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours","volume":"54","author":"Ramage","year":"2005","journal-title":"Gut"},{"key":"2021122309580268300_B47","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S1542-3565(05)00481-7","article-title":"Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: A randomized trial","volume":"3","author":"Arnold","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2021122309580268300_B48","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/oxfordjournals.annonc.a059049","article-title":"A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian trials in medical oncology (I.T.M.O.) group","volume":"6","author":"Di Bartolomeo","year":"1995","journal-title":"Ann Oncol"},{"key":"2021122309580268300_B49","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1200\/JCO.2004.04.024","article-title":"Fluorouracil, doxorubicin, and streptozotocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas","volume":"22","author":"Kouvaraki","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122309580268300_B50","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/1097-0142(19910715)68:2<227::AID-CNCR2820680202>3.0.CO;2-I","article-title":"Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin: Evidence of major therapeutic activity in the anaplastic variants of these neoplasms","volume":"68","author":"Moertel","year":"1991","journal-title":"Cancer"},{"key":"2021122309580268300_B51","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/cncr.11105","article-title":"A 5-decade analysis of 13,715 carcinoid tumors","volume":"97","author":"Modlin","year":"2003","journal-title":"Cancer"},{"key":"2021122309580268300_B52","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1517\/14656566.2013.796931","article-title":"Targeted therapy with kinase inhibitors in aggressive endocrine tumors","volume":"14","author":"Marotta","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"2021122309580268300_B53","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.critrevonc.2014.08.007","article-title":"The evolving field of kinase inhibitors in thyroid cancer","volume":"93","author":"Marotta","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"2021122309580268300_B54","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/MPA.0b013e3181ebb4f0","article-title":"The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: Pheochromocytoma, paraganglioma, and medullary thyroid cancer","volume":"39","author":"Chen","year":"2010","journal-title":"Pancreas"},{"key":"2021122309580268300_B55","doi-asserted-by":"crossref","first-page":"267","DOI":"10.7326\/0003-4819-109-4-267","article-title":"Malignant pheochromocytoma: Effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine","volume":"109","author":"Averbuch","year":"1988","journal-title":"Ann Intern Med"},{"key":"2021122309580268300_B56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-med-061813-012908","article-title":"A tale of two tumors: Treating pancreatic and extrapancreatic neuroendocrine tumors","volume":"66","author":"Halperin","year":"2015","journal-title":"Annu Rev Med"},{"key":"2021122309580268300_B57","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s11912-012-0232-1","article-title":"Pancreatic neuroendocrine and carcinoid tumors: What\u2019s new, what\u2019s old, and what\u2019s different?","volume":"14","author":"Reidy-Lagunes","year":"2012","journal-title":"Curr Oncol Rep"},{"key":"2021122309580268300_B58","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1158\/1078-0432.CCR-12-3458","article-title":"Molecular pathogenesis of neuroendocrine tumors: Implications for current and future therapeutic approaches","volume":"19","author":"Oberg","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2021122309580268300_B59","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11523-012-0226-9","article-title":"Profiling mTOR pathway in neuroendocrine tumors","volume":"7","author":"Cingarlini","year":"2012","journal-title":"Target Oncol"},{"key":"2021122309580268300_B60","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"2021122309580268300_B61","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000100057","article-title":"The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells","volume":"85","author":"Zitzmann","year":"2007","journal-title":"Neuroendocrinology"},{"key":"2021122309580268300_B62","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00280-012-2043-3","article-title":"Overcoming acquired resistance to anticancer therapy: Focus on the PI3K\/AKT\/mTOR pathway","volume":"71","author":"Burris","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122309580268300_B63","doi-asserted-by":"crossref","first-page":"530","DOI":"10.18632\/oncotarget.188","article-title":"Targeting the PI3K\/Akt\/mTOR pathway\u2014Beyond rapalogs","volume":"1","author":"Markman","year":"2010","journal-title":"Oncotarget"},{"key":"2021122309580268300_B64","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"O\u2019Reilly","year":"2006","journal-title":"Cancer Res"},{"key":"2021122309580268300_B65","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1200\/JCO.2010.28.0198","article-title":"Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis","volume":"28","author":"Chiu","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122309580268300_B66","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1172\/JCI37539","article-title":"Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus","volume":"120","author":"Di Nicolantonio","year":"2010","journal-title":"J Clin Invest"},{"key":"2021122309580268300_B67","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1159\/000347063","article-title":"Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas","volume":"97","author":"Bollard","year":"2013","journal-title":"Neuroendocrinology"},{"key":"2021122309580268300_B68","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1530\/ERC-13-0027","article-title":"Are G3 ENETS neuroendocrine neoplasms heterogeneous?","volume":"20","author":"V\u00e9layoudom-C\u00e9phise","year":"2013","journal-title":"Endocr Relat Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2015-0420","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2015-0420","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/21\/7\/875\/41876001\/oncolo_21_7_875.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/21\/7\/875\/41876001\/oncolo_21_7_875.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T04:44:22Z","timestamp":1640321062000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/21\/7\/875\/6401402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,6]]},"references-count":68,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2016,4,6]]},"published-print":{"date-parts":[[2016,7,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2015-0420","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,7,1]]},"published":{"date-parts":[[2016,4,6]]}}}